Phaseline

Targets › IKZF3

IKZF3 (Zinc finger protein Aiolos): drug programs, companies and trials

3 programs from 3 companies in 13 trials: 6 Phase 1, 5 Phase 2, 2 Phase 3; Oncology, Immunology; next expected readout Dec 2026.

Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. (UniProt, Q9UKT9)

Open in Phaseline: the race on IKZF3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbGolcadomide (CC-99282, BMS-986369)
Cereblon E3 ligase modulator; dual IKZF1/IKZF3 degrader
CRBN, IKZF1, IKZF3Phase 3Large B-cell Lymphoma; Follicular Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin …Apr 2027
Q32 Biobempikibart (ADX-914)
IKZF3 degrader (molecular glue)
IKZF3Phase 2Atopic Dermatitis; Alopecia Areata–
Abdullah KhanCC-92480
IKZF1/IKZF3 degrader
IKZF1, IKZF3Phase 1Recurrent Multiple MyelomaDec 2026

Conditions

Large B-cell Lymphoma (1) Follicular Lymphoma (1) Lymphoma, Follicular (1) Lymphoma, Non-Hodgkin (1) Lymphoma, B-Cell (1) Diffuse Large B-cell Lymphoma Refractory (1) Follicular Lymphoma Stage II (1) B-Cell Non-Hodgkin Lymphoma-Recurrent (1) Peripheral T Cells Lymphoma (PTCL) (1) Recurrent Mantle Cell Lymphoma (1) Atopic Dermatitis (1) Alopecia Areata (1)

Modalities

mixed (2), antibody (1)

Companies

Bristol-Myers Squibb (1) Q32 Bio (1) Abdullah Khan (1)

Related targets

IKZF1 (2) CRBN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.